PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?
Precipio and NeoGenomics take different approaches to cancer diagnostics, but which oncology stock looks more compelling now? Let's dive in.
Zacks Investment Research7/16/2026Positive
PRPO
Precipio IncNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$40.97M
P/E Ratio
—
EPS
$-0.44
Beta
1.28
52W High
$33.63
52W Low
$13.80
50-Day MA
$23.96
200-Day MA
$24.27
Dividend Yield
—
Profit Margin
-3.57%
Forward P/E
15.43
PEG Ratio
0.00
About Precipio Inc
Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market. The company is headquartered in New Haven, Connecticut.
Fundamentals
| Revenue (TTM) | $25.83M |
| Gross Profit (TTM) | $11.29M |
| EBITDA | -356,000 |
| Operating Margin | -21.30% |
| Return on Equity | -7.13% |
| Return on Assets | -5.74% |
| Revenue/Share (TTM) | $15.42 |
| Book Value | $7.94 |
| Price-to-Book | 3.02 |
| Price-to-Sales (TTM) | 1.59 |
| EV/Revenue | 1.689 |
| EV/EBITDA | 46.77 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 36.20% |
| Shares Outstanding | $1.79M |
| Float | $1.40M |
| % Insiders | 12.65% |
| % Institutions | 17.66% |
Historical Volatility
HV 10-Day
72.26%
HV 20-Day
65.87%
HV 30-Day
57.79%
HV 60-Day
56.97%
HV Rank
25.4%
Volatility is currently expanding
Latest News
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
NEW HAVEN, Conn., June 12, 2026 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately. Votes must be received by 11:59 p.m., Eastern Time, on June 14, 2026, to be voted at the Annual Meeting.
GlobeNewsWire6/12/2026Neutral
Precipio to Present at the Planet MicroCap Las Vegas
NEW HAVEN, Conn., June 11, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that it will be presenting at the Planet MicroCap Las Vegas 2026 on Wednesday, June 17, 2026, at 9:00 AM (Local Time, 12:00pm EST) at the Bellagio Resort & Hotel. Ilan Danieli, CEO and Zaki Sabet, COO of Precipio will be hosting the presentation and answering questions at the conclusion.
GlobeNewsWire6/11/2026Neutral
Precipio Stock Slips Post Q1 Earnings Despite Revenue Growth
PRPO's first-quarter 2026 sales are driven by pathology momentum, but CMS reimbursement cuts and higher spending squeeze margins and widen losses.
Zacks Investment Research5/22/2026Neutral
Precipio, Inc. (PRPO) Q1 2026 Earnings Call Transcript
Precipio, Inc. (PRPO) Q1 2026 Earnings Call Transcript
Seeking Alpha5/18/2026Neutral
The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio
AI demand and pipeline growth headline top Zacks stock reports on NVIDIA, Mastercard and AbbVie.
Zacks Investment Research5/13/2026Neutral
Precipio Announces Q1-2026 Shareholder Update Call
NEW HAVEN, Conn., May 06, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM ET.
GlobeNewsWire5/6/2026Neutral
Precipio, Inc. (PRPO) Q4 2025 Earnings Call Prepared Remarks Transcript
Precipio, Inc. (PRPO) Q4 2025 Earnings Call Prepared Remarks Transcript
Seeking Alpha4/2/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PRPO and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026